Back to Search Start Over

Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study

Authors :
Koichi Hirata
Mika Komori
Kaname Ueda
Anthony J. Zagar
Yongin Kim
Dena H. Jaffe
Yasuhiko Matsumori
Takao Takeshima
Source :
Drugs - Real World Outcomes, Vol 10, Iss 3, Pp 415-428 (2023)
Publication Year :
2023
Publisher :
Adis, Springer Healthcare, 2023.

Abstract

Abstract Background Knowledge of patient outcomes and treatment effectiveness associated with acute migraine treatments in Japan is lacking. Objective To describe patient-reported outcomes (PROs) and treatment effectiveness in three acute treatment groups from OVERCOME (Japan): over-the-counter (OTC) only, prescription nonsteroidal anti-inflammatory drugs/acetaminophen (Rx-NSAIDs/ACE) only, and triptans. Methods OVERCOME (Japan) was an observational, cross-sectional, population-based web survey of people with migraine (July–September 2020). PROs, including the Migraine-Specific Quality of Life Questionnaire (MSQ), Migraine Interictal Burden Scale (MIBS-4), Migraine Disability Assessment (MIDAS), and Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI-M), were compared pairwise between treatment groups. Logistic regression was used to examine treatment effectiveness. Results The analysis included 9075 survey respondents (OTC only: n = 5791; Rx-NSAIDs/ACE only: n = 751; triptans: n = 2533). Triptan users reported the lowest MSQ scores, most severe disability (MIDAS: 20.7% versus 6.3% and 11.6%) and severe interictal burden (MIBS-4: 50.1% versus 21.2% and 19.8%), and greatest work impairment (WPAI-M: 50.4% versus 32.2% and 30.8%) compared with the OTC and Rx-NSAIDs/ACE groups, respectively. Treatment effectiveness was very poor-to-poor for 60.9%, 43.1%, and 47.6% of the triptan, OTC, and Rx-NSAIDs/ACE groups, respectively. Severe interictal burden was significantly associated with insufficient treatment effectiveness (odds ratios, severe versus no burden: 0.47 [95% confidence interval: 0.40–0.54], 0.56 [0.35–0.89], and 0.41 [0.32–0.52], for the OTC, Rx-NSAIDs/ACE, and triptan groups, respectively). Conclusion People with high migraine burden used triptans for acute treatment, but many reported poor treatment effectiveness. Education may be required to promote better treatments, including earlier introduction of migraine-specific acute and preventive medications.

Details

Language :
English
ISSN :
21991154 and 21989788
Volume :
10
Issue :
3
Database :
Directory of Open Access Journals
Journal :
Drugs - Real World Outcomes
Publication Type :
Academic Journal
Accession number :
edsdoj.90a0414869bb48debc6a4158d4d97ec8
Document Type :
article
Full Text :
https://doi.org/10.1007/s40801-023-00368-0